Loading clinical trials...
Loading clinical trials...
This study aims to identify the prognostic role of procalcitonin (PCT), soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), the soluble form of the urokinase plasminogen activator receptor (suPAR), highly sensitive C-reactive protein (hs-CRP), Interleukin-6 (IL-6), and azurocidin 1 (AZU1) in 28-day mortality for patients with sepsis in Emergency Department.
The levels of the specified biomarkers were measured upon patient arrival at the Emergency Department (ED) and analyzed their correlation with 28-day mortality. The values of these biomarkers were monitored over the initial three days following admission to the ED, aiming to explore their potential in guiding the de-escalation of antibiotic treatment. Considering their prognostic significance, the main goal is to develop a novel scoring system tailored for use in the emergency department setting.
Age
18 - 90 years
Sex
ALL
Healthy Volunteers
No
Cluj County Hospital Emergency Department
Cluj-Napoca, Cluj, Romania
Start Date
November 9, 2020
Primary Completion Date
December 6, 2022
Completion Date
April 30, 2023
Last Updated
June 7, 2024
67
ACTUAL participants
ELISA Sepsis Biomarkers dosage
DIAGNOSTIC_TEST
Lead Sponsor
Iuliu Hatieganu University of Medicine and Pharmacy
NCT07486401
NCT07323485
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions